Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Mirati Therapeutics...

    Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-02T09:00:03+05:30  |  Updated On 17 Aug 2021 11:42 AM IST

    Out of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and four with colorectal cancer.


    New Delhi: An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumour size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday.


    Investors have been keen to see how Mirati's data stack up against results for a similar drug, AMG510, under development by Amgen Inc. Both target a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancer cases, 3-5% of colorectal cancers and up to 2% of other solid tumour cancers.


    Out of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and four with colorectal cancer.


    Three of the lung cancer patients had a "partial response," defined as a 30% or more reduction in tumour size. One of the evaluated colorectal cancer patients also had a partial response.


    The lung cancer responses are considered "unconfirmed" since patients have not had follow-up scans.


    "The signs are there, but the numbers are small," lead study investigator Dr Pasi Janne, director of thoracic oncology at Boston's Dana-Farber Cancer Institute, told Reuters. "It is too early to say anything about the durability of response."


    All of the responding patients received the highest dose used in the dose-ranging study - 600 milligrams given twice a day, he said.


    Cancer was stabilized in the other evaluated patients, including two with cancer of the appendix, Janne said, although one trial patient's cancer worsened.


    Janne said side effects of MRTX849 have been mostly mild, including diarrhoea and nausea, but two patients had higher-grade toxicity including increased levels of pancreatic enzymes, although they did not exhibit any symptoms of pancreatic inflammation.


    Read Also: Amgen drug AMG510 shrinks lung cancer tumours in half of the patients in an early-stage trial


    The first-in-human results were presented in Boston at the International Conference on Molecular Targets and Cancer Therapeutics.


    Amgen has reported Phase 1 trial results showing that tumours shrank in about half of advanced lung cancer patients given a 960 mg daily dose of AMG510, but the response rate in colon cancer has been much lower. The U.S. Food and Drug Administration has granted "fast track" status to AMG510 for lung cancer.


    By Deena Beasley


    Read Also: Amgen drug shows a high response rate in small lung, colon cancer trial

    AmgencancerClinical Trialcolorectal cancerlung cancerMirati Therapeuticsoncologyphase-1tumour
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok